X4 Pharmaceuticals Inc (XFOR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.52 is considered Overvalued compared with the five-year average of -1.96. The fair price of X4 Pharmaceuticals Inc (XFOR) is between 1.21 to 3.37 according to relative valuation method. Compared to the current price of 3.40 USD , X4 Pharmaceuticals Inc By Overvalued By 0.9%.

Relative Value

Fair Zone

1.21-3.37

Current Price：3.40

0.9%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is X4 Pharmaceuticals Inc (XFOR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

X4 Pharmaceuticals Inc (XFOR) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 21.54, the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 12.08, the current P/B ratio is about -100.00% higher. X4 Pharmaceuticals Inc (XFOR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -117.28%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -104.21%, the current FCF yield is about -100.00% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for XFOR competitors is 0.81, providing a benchmark for relative valuation. X4 Pharmaceuticals Inc Corp (XFOR.O) exhibits a P/S ratio of 3.52, which is 334.54% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of XFOR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of XFOR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is XFOR currently overvalued or undervalued?

What is X4 Pharmaceuticals Inc (XFOR) fair value?

XFOR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of X4 Pharmaceuticals Inc (XFOR) is between 1.21 to 3.37 according to relative valuation method.

How does XFOR's valuation metrics compare to the industry average?

The average P/S ratio for XFOR's competitors is 0.81, providing a benchmark for relative valuation. X4 Pharmaceuticals Inc Corp (XFOR) exhibits a P/S ratio of 3.52, which is 334.54% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for X4 Pharmaceuticals Inc (XFOR) as of Mar 03 2026?

As of Mar 03 2026, X4 Pharmaceuticals Inc (XFOR) has a P/B ratio of 0.00. This indicates that the market values XFOR at 0.00 times its book value.

What is the current FCF Yield for X4 Pharmaceuticals Inc (XFOR) as of Mar 03 2026?

As of Mar 03 2026, X4 Pharmaceuticals Inc (XFOR) has a FCF Yield of 0.00%. This means that for every dollar of X4 Pharmaceuticals Inc's market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for X4 Pharmaceuticals Inc (XFOR) as of Mar 03 2026?

As of Mar 03 2026, X4 Pharmaceuticals Inc (XFOR) has a Forward P/E ratio of -0.52. This means the market is willing to pay $-0.52 for every dollar of X4 Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for X4 Pharmaceuticals Inc (XFOR) as of Mar 03 2026?

As of Mar 03 2026, X4 Pharmaceuticals Inc (XFOR) has a Forward P/S ratio of 3.52. This means the market is valuing XFOR at $3.52 for every dollar of expected revenue over the next 12 months.

XFOR Valuation